Vimarsana
Biggest News Aggregation in the World

Page 6 - Applied Genetics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Applied Genetics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Applied Genetics Today - Breaking & Trending Today

CloudLIMS' Complimentary Talk on Regulatory Challenges in Biobanking - Vimarsana News

CloudLIMS' Complimentary Talk on Regulatory Challenges in Biobanking

CloudLIMS, a leading provider of laboratory informatics, is pleased to announce its talk at the IBS 2022 Virtual Symposium scheduled on February 22, 2022.

Today's abundance of wine grape varieties descended from fruit bred in western Asia - Vimarsana News

Today's abundance of wine grape varieties descended from fruit bred in western Asia

Today's abundance of wine grape varieties descended from fruit bred in western Asia.

Source: go.com
Today's Abundance of Wine Grape Varieties Descended from Fruit Bred in Western Asia - Vimarsana News

Today's Abundance of Wine Grape Varieties Descended from Fruit Bred in Western Asia

(Inside Science) -- Many of the varieties of grapes used in today's wines are hundreds of years old. Genetic analysis shows that although these vines were first cultivated in Western Europe, new research confirms that every popular wine grape shares an ancestor.

Today's Abundance of Wine Grape Varieties Descended from Fruit Bred in Western Asia - Vimarsana News

Today's Abundance of Wine Grape Varieties Descended from Fruit Bred in Western Asia

(Inside Science) -- Many of the varieties of grapes used in today's wines are hundreds of years old. Genetic analysis shows that although these vines were first cultivated in Western Europe, new research confirms that every popular wine grape shares an ancestor.

Pfizer Invests $68.5 Million in New State-of-the-Art Facility in Durham, North Carolina to Further Advance Gene Therapy Capabilities - Vimarsana News

Pfizer Invests $68.5 Million in New State-of-the-Art Facility in Durham, North Carolina to Further Advance Gene Therapy Capabilities

The Durham facility is part of an $800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer’s continued investment in gene therapy research, development, and manufacturing.